FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 776 - Advisory Council for the Elimination of Tuberculosis - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	Advisory Council for the Elimination of Tuberculosis	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	776
Original Establishment Date	8/15/1990	Committee Status	Chartered
Actual Termination Date		Committee URL	https://www.cdc.gov/faca/committees/acet.html
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	10
Terminated This FY	No	Designated Fed Officer Position Title*	Designated Federal Officer
Merged This FY	No	Designated Federal Officer Prefix	Dr.
Current Charter Date	3/15/2025	Designated Federal Officer First Name*	Carla
Date Of Renewal Charter	3/15/2027	Designated Federal Officer Middle Name
Projected Termination Date		Designated Federal Officer Last Name*	Winston
Exempt From Renewal*	No	Designated Federal Officer Suffix	Ph.D., M.A.
Specific Termination Authority		Designated Federal Officer Phone*	(404) 718-8308
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*	(404) 718-8308
Specific Establishment Authority*	Section 3I7E(f) of the PHS Act, [42 U.S.C. §247b-6(f)], as amended; (Section 2(b)), Public Law 101-368	Designated Federal Officer Email*	ctw3@cdc.gov
Effective Date Of Authority*	8/15/1990
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The Advisory Council for the Elimination of Tuberculosis (ACET or “The Council”) accomplishes its purpose deliberating and making recommendations to the U.S. Department of Health and Human Services (HHS) Secretary, the HHS Assistant Secretary for Health, and the Centers for Disease Control and Prevention (CDC) Director on timely topics for the U.S. elimination of tuberculosis (TB). The Council meets regularly to address specific TB elimination issues including: (1) policies, strategies, objectives, and priorities; (2) the development and application of new technologies; (3) guidance and review on CDC’s TB Prevention Research portfolio and program priorities; and (4) review of the extent to which progress has been made toward eliminating TB.
How is membership balanced?*	ACET’s membership is composed of recognized experts with knowledgeable points of view in the fields of public health, epidemiology, immunology, infectious diseases, pulmonary disease, pediatrics, tuberculosis, microbiology, and preventive health care delivery. To achieve the highest quality comprehensive recommendations for TB control, it is critical that individuals chosen for membership on ACET have significant expertise in TB control, public health, academia, and/or TB research, including cross-cutting knowledge and experience in the various components of TB control. The recruitment process ensures that the membership is balanced by geographic region, expertise, and perspective. ACET also requires one member who has had TB disease or who is the parent of a child who had TB disease. The varied expertise and experience of this council’s membership is necessary to succeed in the elimination of TB.
How frequent & relevant are cmte mtgs?*	The Council met once in fiscal year 2025 on issues relevant to elimination of TB as outlined in the Council’s charter. Meeting outcomes may include providing recommendations and guidance to HHS and CDC regarding policies, strategies, objectives, and priorities; and addressing the development and application of new technologies. At the December 3-4, 2024, meeting ACET provided advice, recommendations, and robust discussions on a number of critical issues. ACET heard an overview of TB screenings for new arrivals by the U.S. Immigration and Customs Enforcement Health Service Corps. They discussed the current landscape, challenges, and future directions for CDC’s National TB Surveillance System and molecular surveillance and heard an update on the TB Epidemiologic Studies Consortium III activities. ACET discussed the evaluation of the Think. Test. Treat TB campaign, CDC’s first national latent TB infection (LTBI) health communications campaign. Examples of accomplishments during fiscal year 2025 are summarized below. ACET reviewed the findings of the Drug Shortage Workgroup and after discussion voted on three recommendations sent to the HHS Secretary in January 2025. The Drug Shortage Workgroup met once in FY 2025. These recommendations included: 1) suggesting the addition of the four most common oral TB drugs, specifically isoniazid, rifampin, pyrazinamide and ethambutol (including the most frequently used formulations and strengths) to the FDA Essential Medications List; 2) strongly encouraging exploring a mechanism for accessing the Global Drug Facility for procurement of TB drugs and diagnostics in shortage or otherwise not available in the US; and 3) formally inviting the HHS Supply Chain and Resilience Coordinator to attend one of our biannual ACET meetings to learn firsthand about the challenges of TB drug shortages and work with ACET to develop solutions. During the December 2024 meeting ACET also voted to establish the Biennial Letter Workgroup whose charge is to 1) evaluate the status of recommendations from the previous biennial letter submitted to HHS; 2) engage with ACET members on the current status of TB elimination in the US; and 3) draft a new biennial letter with updated data and provide findings, observations, and outcomes for review and vote by the full ACET. The Biennial Letter workgroup met twice in FY 2025 and are expected to bring their findings to the December 2025 ACET meeting for full Council discussion and deliberation. Additional accomplishments include: In response to the 2022 ACET recommendation that CDC define the key components of an effective public health TB workforce in the US, CDC included in the 2025 Tuberculosis Elimination and Laboratory Cooperative Agreement Funding Opportunity PS25-0003, the requirement that by the end of year one, grantees will provide the following information to be used in a national TB workforce assessment: a list of current positions with titles and percent Full Time Equivalent (FTE), both filled and vacant​, and a list of additional positions and percent FTE believed necessary to fully execute the program’s TB elimination plan​. Additionally, state and larger local TB programs will provide assessment of gaps in workforce needs. In response to the 2024 ACET recommendation to review the data analysis and recommendations presented in the National TB Coalition of America (NTCA) Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings in regard to existing CDC guidelines and policy related to TB isolation, a workgroup was formed in August 2024 with members from the CDC’s Division of TB Elimination, National Institute for Occupational Safety and Health, and Division of Healthcare Quality Promotion. The ​Workgroup reviewed the NTCA isolation guidelines, evidence summary, and accompanying suite of published papers as well as systematically reviewing evidence on isolation in healthcare settings.​ The workgroup concluded in April 2025 with no change to recommendations to CDC.
Why advice can't be obtained elsewhere?*	Although TB is both preventable and curable, this life-threatening disease remains a serious problem in the United States. TB disease and LTBI are present in every state; in rural areas as well as cities; in schools, workplaces, and homes; and in places where persons spend time in close contact with others (e.g., correctional facilities and homeless shelters). Innovative and expanded approaches are required for eliminating TB in the United States, especially as concerns increase regarding antimicrobial resistance and complexity of TB cases. CDC has proposed multiple interventions for accelerating the decrease in U.S. TB incidence, including increasing LTBI testing and treatment among populations at high risk, enhancing detection and treatment of TB cases to reduce transmission, and improving TB treatment regimens to increase the proportion of TB patients successfully completing treatment. ACET is the only federal advisory committee chartered to address U.S. TB elimination; it is continually active, and its advice, recommendations, and guidance are crucial as HHS and its public health partners to develop, implement, and evaluate innovative and expanded approaches to TB elimination.
Why close or partially close meetings?	N/A
Recommendation Remarks	Karen Elkins stepped down 9/15/2025; Stephen Martin Retired 10/1/2025; Gary Rosselle retired 10/30/2024; Robert Benjamin retired 7/2025; Susan Ruwe retired 1/2025; Masahiro Narita retired 7/2025; Valerie Adelson retired 8/2025; Colin Puzo Smith retired 11/2024; Susam Rappaport retired 11/1/2024

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	Yes	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	Yes	Action Other	No
Outcome Increased Customer Satisfaction	Yes	Action Comment	CDC works closely with the Chair of ACET to identify priorities and issues to be addressed at Council meetings. Prior to the meetings, CDC works with ACET to prepare agendas and provides background materials to Council members. CDC also provides support to ACET workgroups to focus on priority issues under the authority of the Council.
Outcome Implement Laws/Reg Requirements	No	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	N/A	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	There was no apparent cost-savings in comparison to the previous year.	Grants Review Comment	ACET does not perform grant reviews.
Number Of Recommendations*	218	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	The recommendations for FY2025 fall under these categories: Drug Shortages and the ACET Biennial Letter Workgroup formation.	Access Agency Website	Yes
% of Recs Fully Implemented*	73.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	Since 2007, 160 recommendations were fully implemented.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	14.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	Since 2007, 31 recommendations remain partially implemented. CDC is working on a routine basis to update partially implemented recommendations. Currently 27 recommendations have not been implemented by the agency, of which 15 were directed to HHS, 10 were directed to CDC, and 2 was directed to FDA.	Access Other	No
Agency Feedback*	Yes	Access Comment	https://www.cdc.gov/faca/committees/acet.html
Agency Feedback Comment*	Feedback is provided to ACET at Council meetings; by written and electronic correspondence, and in reports published in online-accessible formats and journals. Additional information is available at https://www.cdc.gov/faca/committees/acet.html	Narrative Description*	The Council supports CDC’s mission by bringing TB issues to national attention, particularly those having an impact on national health outcomes goals. The Council reviews and evaluates CDC activities and national policies that impact TB control, provides input and recommendations, and monitors TB control and elimination efforts. The Council also forms issue-specific workgroups, provides direct feedback to HHS and CDC during meetings, and communicates with the Secretary, Department of Health and Human Services (HHS).

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:43 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Health Public Health Treatment Medicine Diseases Health and Health Research Illnesses Research Research and Development

Custom Links

Committee Level Reports